The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors.
 
Chang Liu
No Relationships to Disclose
 
Miao Zhang
No Relationships to Disclose
 
Jiajia Yuan
No Relationships to Disclose
 
Dan Liu
No Relationships to Disclose
 
Jifang Gong
No Relationships to Disclose
 
Yi Zhu
Employment - Ionova
Leadership - Ionova
 
Lishan Lin
Employment - Ionova
Leadership - Ionova
Travel, Accommodations, Expenses - Ionova
 
Yongkui Sun
Employment - Ionova
Leadership - Ionova
Travel, Accommodations, Expenses - Ionova
 
Johannes Nippgen
Employment - Ionova
Leadership - Ionova
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche; Sanofi
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); CANbridge Pharmaceuticals (Inst); Jacobio (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)